X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
AMAR REMEDIES Quarterly Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES Quarterly Results   (AMAD)

Here are the latest quarterly results of AMAR REMEDIES. For more details, see the AMAR REMEDIES financial fact sheet and AMAR REMEDIES share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

AMAR REMEDIES Quarterly Results

No. of Mths
Qtr. Ending
3
Sep-11
3
Dec-11
3
Mar-12
3
Jun-12
3
Sep-12
3
Dec-12
3
Mar-13
3
Jun-13
8-Qtr Chart
Click to enlarge
Net Sales Rs m1,5911,6491,6931,8111,5241,6301,310452 
Other income Rs m014525420 
Turnover Rs m1,5911,6631,6981,8131,5291,6341,312452 
Expenses Rs m1,3591,4051,4131,4371,3631,4471,219531 
Gross profit Rs m23224427937316018391-80 
Depreciation Rs m2828284331474721 
Interest Rs m8890104116119124139146 
Profit before tax Rs m1161401522161516-93-247 
Tax Rs m181823643300 
Profit after tax Rs m981221291521213-93-247 
Gross profit margin %14.614.816.520.610.511.26.9-17.7 
Effective tax rate %15.512.915.129.620.018.80.00.0 
Net profit margin %6.27.47.68.40.80.8-7.1-54.6 
Diluted EPS Rs 3.7 4.7 4.9 5.8 0.5 0.5 -3.6 -9.4  
Diluted EPS (TTM) Rs 15.0 16.1 17.3 19.2 15.9 11.7 3.2 -12.0  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

More Consumer Products Company Quarterly Results:   GSK PHARMA  FDC LTD.  ASTRAZENECA PHARMA  LUPIN LTD  FRESENIUS KABI ONCO.  

Compare AMAR REMEDIES With:   GSK PHARMA  FDC LTD.  ASTRAZENECA PHARMA  LUPIN LTD  FRESENIUS KABI ONCO.  

Compare AMAR REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Views on news

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AMAR REMEDIES

AMAR REMEDIES 5-YR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS